QQQ $ 473.07 $ -2.30 (-0.48 %)
DIA $ 413.74 $ -1.11 (-0.27 %)
SPY $ 559.58 $ -1.19 (-0.21 %)
TLT $ 96.94 $ -0.73 (-0.75 %)
GLD $ 231.31 $ -1.08 (-0.46 %)
$ 1.51
-- x --
-- x --
-- - --
$ 0.20 - $ 1.52
120,938
na
1.78M
$ -4.03
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 03-28-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-23-2023 12-31-2022 10-K
8 11-07-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-30-2022 12-31-2021 10-K
12 11-02-2021 09-30-2021 10-Q
13 07-26-2021 06-30-2021 10-Q
14 05-04-2021 03-31-2021 10-Q
15 03-01-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-11-2020 06-30-2020 10-Q
18 05-05-2020 03-31-2020 10-Q
19 02-20-2020 12-31-2019 10-K
20 10-28-2019 09-30-2019 10-Q
21 08-01-2019 06-30-2019 10-Q
22 05-03-2019 03-31-2019 10-Q
23 03-12-2019 12-31-2018 10-K
24 11-02-2018 09-30-2018 10-Q
25 08-03-2018 06-30-2018 10-Q
26 05-07-2018 03-31-2018 10-Q
27 03-12-2018 12-31-2017 10-K
28 11-06-2017 09-30-2017 10-Q
29 07-28-2017 06-30-2017 10-Q
30 05-08-2017 03-31-2017 10-Q
31 03-15-2017 12-31-2016 10-K
32 11-07-2016 09-30-2016 10-Q
33 08-08-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 03-09-2016 12-31-2015 10-K
36 11-09-2015 09-30-2015 10-Q
37 08-13-2015 06-30-2015 10-Q
38 05-12-2015 03-31-2015 10-Q
39 03-26-2015 12-31-2014 10-K
40 11-13-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 agile-therapeutics-q1-2024-adj-eps-063-misses-051-estimate-sales-572m-beat-375m-estimate

Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of ...

 agile-therapeutics-q4-adj-146-misses-092-estimate-sales-362m-miss-407m-estimate

Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of ...

 why-agile-therapeutics-agrx-stock-is-down-60

Agile Therapeutics shares are trading lower by 61% during Tuesday's session. The company announced the suspension of its tr...

 agile-therapeutics-reveals-final-delisting-notice-from-nasdaq

Suspension of trading in the Company's common stock on the Nasdaq exchange will be effective at the open of trading on Marc...

 earnings-scheduled-for-march-22-2024

Companies Reporting Before The Bell • Agile Therapeutics (NASDAQ:AGRX) is likely to report quarterly loss at $0.54 per share o...

 maxim-group-downgrades-agile-therapeutics-to-hold

Maxim Group analyst Naz Rahman downgrades Agile Therapeutics (NASDAQ:AGRX) from Buy to Hold.

Core News & Articles

https://www.washingtonpost.com/world/2024/03/04/france-abortion-constitution/

 why-etsy-shares-are-trading-lower-by-around-8-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Etsy, Inc.

 whats-going-on-with-women-health-focused-agile-therapeutics-stock-today

Agile Therapeutics stock rises on premarket trading, exercising warrants for $4.8M gross proceeds with reduced exercise price o...

 why-nvidia-shares-are-trading-higher-by-around-14-here-are-20-stocks-moving-premarket

Shares of NVIDIA Corporation (NASDAQ: NVDA) rose sharply in today’s pre-market trading after the company reported better-than-...

 agile-therapeutics-announces-extension-granted-by-nasdaq-hearings-panel-to-regain-compliance-until-march-25-2024-sees-fy23-revenue-20m-21m

Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Req...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION